It's either Pfizer because it's main cancer drug is going off patent in a few years or someone who sees potential in a drug not targeting surface antigen markers which is old IP . Cell nucleus penetrative antibodies are the new potential in cancer treatment. Novel and unique we are.
Ann: New PAT-DX3 data demonstrates synthetic lethality, page-25
Add PAB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.8¢ |
Change
0.000(0.00%) |
Mkt cap ! $16.46M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 23 | 6624869 | 0.7¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.8¢ | 1994916 | 4 |
View Market Depth
| Last trade - 10.08am 14/05/2024 (20 minute delay) ? |
| PAB (ASX) Chart |
Day chart unavailable